Equities analysts expect Voyager Therapeutics Inc (NASDAQ:VYGR) to announce $3.75 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Voyager Therapeutics’ earnings, with estimates ranging from $2.00 million to $5.00 million. Voyager Therapeutics posted sales of $2.58 million in the same quarter last year, which would indicate a positive year over year growth rate of 45.3%. The firm is expected to report its next quarterly earnings results on Tuesday, August 6th.

On average, analysts expect that Voyager Therapeutics will report full year sales of $25.14 million for the current fiscal year, with estimates ranging from $5.00 million to $81.57 million. For the next year, analysts anticipate that the firm will report sales of $43.37 million, with estimates ranging from $7.60 million to $95.57 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Voyager Therapeutics.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.81) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.65 by ($1.46). The firm had revenue of $5.20 million for the quarter, compared to the consensus estimate of $3.00 million. Voyager Therapeutics had a negative return on equity of 129.67% and a negative net margin of 804.55%.

VYGR has been the subject of several recent research reports. Cowen reissued a “buy” rating on shares of Voyager Therapeutics in a report on Wednesday, February 27th. Cantor Fitzgerald initiated coverage on Voyager Therapeutics in a report on Tuesday, March 5th. They set an “overweight” rating and a $27.00 price objective for the company. Zacks Investment Research cut Voyager Therapeutics from a “buy” rating to a “hold” rating and set a $12.00 price objective for the company. in a report on Friday, February 22nd. ValuEngine upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 23rd. Finally, HC Wainwright restated a “buy” rating and set a $22.00 target price on shares of Voyager Therapeutics in a research report on Monday, May 6th. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $24.11.

Shares of NASDAQ:VYGR opened at $23.53 on Thursday. The stock has a market cap of $866.66 million, a price-to-earnings ratio of -8.56 and a beta of 2.47. Voyager Therapeutics has a 1-year low of $7.76 and a 1-year high of $25.74.

Several institutional investors have recently bought and sold shares of the company. SG3 Management LLC bought a new stake in shares of Voyager Therapeutics in the first quarter valued at $57,000. Metropolitan Life Insurance Co. NY raised its stake in shares of Voyager Therapeutics by 449.4% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock valued at $85,000 after buying an additional 7,401 shares during the period. BNP Paribas Arbitrage SA raised its stake in shares of Voyager Therapeutics by 74,766.7% in the first quarter. BNP Paribas Arbitrage SA now owns 4,492 shares of the company’s stock valued at $86,000 after buying an additional 4,486 shares during the period. Bank of America Corp DE raised its stake in shares of Voyager Therapeutics by 211.0% in the fourth quarter. Bank of America Corp DE now owns 10,637 shares of the company’s stock valued at $100,000 after buying an additional 7,217 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in shares of Voyager Therapeutics by 66.8% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,380 shares of the company’s stock valued at $101,000 after buying an additional 4,559 shares during the period. Institutional investors own 73.78% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

Further Reading: How Do Mutual Funds Work?

Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.